Peak Bio, Inc.

Ignyte Acquisition Corp. (Nasdaq: IGNY) priced its initial public offering in 2021 as a blank-check company targeting the biotechnology and pharmaceutical sector. In April 2022, Ignyte announced a definitive business combination agreement with Peak Bio, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugate therapies. The transaction has since closed, bringing Peak Bio into the public markets through the completed merger. The deal is recorded as closed in current SPAC market data. Investors and analysts tracking biotech SPAC activity can access comprehensive filing histories, deal timelines, and comparable transaction data for Ignyte Acquisition Corp. and thousands of other vehicles by signing up at SpacDesk.

SPAC Counterparty (1)